NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT03223662 2018-10-30
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00006245 2013-06-24
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045526 2013-06-04
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003326 2008-07-24
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown